SELDI-TOF MS Proteomics in Breast Cancer
SELDI-TOF MS Proteomics in Breast Cancer
Background: Proteomic profiling is a rapidly developing technology that may enable early disease screening and diagnosis. Surface-enhanced laser desorption ionization–time of flight mass spectrometry (SELDI-TOF MS) has demonstrated promising results in screening and early detection of many diseases. In particular, it has emerged as a high-throughput tool for detection and differentiation of several cancer types. This review aims to appraise published data on the impact of SELDI-TOF MS in breast cancer.
Methods: A systematic literature search between 1965 and 2009 was conducted using the PubMed, EMBASE, and Cochrane Library databases. Studies covering different aspects of breast cancer proteomic profiling using SELDI-TOF MS technology were critically reviewed by researchers and specialists in the field.
Results: Fourteen key studies involving breast cancer biomarker discovery using SELDI-TOF MS proteomic profiling were identified. The studies differed in their inclusion and exclusion criteria, biologic samples, preparation protocols, arrays used, and analytical settings. Taken together, the numerous studies suggest that SELDI-TOF MS methodology may be used as a fast and robust approach to study the breast cancer proteome and enable the analysis of the correlations between proteomic expression patterns and breast cancer.
Conclusion: SELDI-TOF MS is a promising high-throughput technology with potential applications in breast cancer screening, detection, and prognostication. Further studies are needed to resolve current limitations and facilitate clinical utility.
breast cancer, seldi, proteomics, biomarkers
133-147
Zeidan, Bashar A.
acd18415-22ee-43b8-a102-a36ea22dd0af
Cutress, Ramsey I.
68ae4f86-e8cf-411f-a335-cdba51797406
Hastie, Claire
00b5a5a1-da64-4c54-be0e-06e2e6ffe6a0
Mirnezami, Alex H.
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Townsend, Paul A.
a2680443-664e-46d0-b4dd-97456ba810db
30 June 2009
Zeidan, Bashar A.
acd18415-22ee-43b8-a102-a36ea22dd0af
Cutress, Ramsey I.
68ae4f86-e8cf-411f-a335-cdba51797406
Hastie, Claire
00b5a5a1-da64-4c54-be0e-06e2e6ffe6a0
Mirnezami, Alex H.
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Townsend, Paul A.
a2680443-664e-46d0-b4dd-97456ba810db
Zeidan, Bashar A., Cutress, Ramsey I., Hastie, Claire, Mirnezami, Alex H., Packham, Graham and Townsend, Paul A.
(2009)
SELDI-TOF MS Proteomics in Breast Cancer.
Clinical Proteomics, 5 (3-4), .
(doi:10.1007/s12014-009-9032-5).
Abstract
Background: Proteomic profiling is a rapidly developing technology that may enable early disease screening and diagnosis. Surface-enhanced laser desorption ionization–time of flight mass spectrometry (SELDI-TOF MS) has demonstrated promising results in screening and early detection of many diseases. In particular, it has emerged as a high-throughput tool for detection and differentiation of several cancer types. This review aims to appraise published data on the impact of SELDI-TOF MS in breast cancer.
Methods: A systematic literature search between 1965 and 2009 was conducted using the PubMed, EMBASE, and Cochrane Library databases. Studies covering different aspects of breast cancer proteomic profiling using SELDI-TOF MS technology were critically reviewed by researchers and specialists in the field.
Results: Fourteen key studies involving breast cancer biomarker discovery using SELDI-TOF MS proteomic profiling were identified. The studies differed in their inclusion and exclusion criteria, biologic samples, preparation protocols, arrays used, and analytical settings. Taken together, the numerous studies suggest that SELDI-TOF MS methodology may be used as a fast and robust approach to study the breast cancer proteome and enable the analysis of the correlations between proteomic expression patterns and breast cancer.
Conclusion: SELDI-TOF MS is a promising high-throughput technology with potential applications in breast cancer screening, detection, and prognostication. Further studies are needed to resolve current limitations and facilitate clinical utility.
This record has no associated files available for download.
More information
Published date: 30 June 2009
Keywords:
breast cancer, seldi, proteomics, biomarkers
Identifiers
Local EPrints ID: 142283
URI: http://eprints.soton.ac.uk/id/eprint/142283
PURE UUID: d2282a86-8eca-41e6-9ca9-473190960bf5
Catalogue record
Date deposited: 31 Mar 2010 14:12
Last modified: 14 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
Bashar A. Zeidan
Author:
Claire Hastie
Author:
Paul A. Townsend
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics